Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 20, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Appoints David Marek as Chief Commercial Officer

NEW YORK, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
August 08, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

Both STRIDE-1 Phase 3 trial in TRD and GEMINI Phase 3 trial in MDD for AXS-05 on track for readout of topline results in 2H 2019 MOMENTUM Phase 3 trial of AXS-07 in migraine on track for readout of...
July 30, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019

Axsome to host conference call and webcast on Thursday, August 8, 2019 at 8:00 AM Eastern Time NEW YORK, July 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
July 29, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility

Extends interest-only period and time to access additional funding NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company...
July 01, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes

NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
June 24, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

First patient enrolled in placebo-controlled GEMINI study Topline results anticipated in 2H 2019 NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
June 07, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting

Placebo-controlled Phase 3 trial of AXS-05 in MDD on track to start in 2Q 2019 Topline results from both STRIDE-1 Phase 3 trial in TRD and planned placebo-controlled Phase 3 trial in MDD for AXS-05...
May 21, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting

NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
May 09, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing...
May 06, 2019 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine

Topline results now anticipated in 2H 2019 Trial enriched with only patients with history of inadequate response to prior migraine treatments Trial compares AXS-07 to placebo and active comparator ...